need to be added to my ealry alert list ! PM me ;-)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
0.01 coming again!!!! might pop again as shorts covering!
Short squeeze play now!
0.0074 X 0.0075 short squeeze might continues!
Cancer Genetics, Inc. Finalizes Purchase of Los Angeles-based Molecular Profiling Laboratory, Response Genetics, Inc., Adding $10-$12M in Annual Revenue and Establishing a National Clinical Sales Footprint
PUBLISHED ON: Monday, October 12th, 2015 View all Media
RUTHERFORD, N.J., October 12, 2015 — Cancer Genetics, Inc. (Nasdaq:CGIX; “CGI” or “the Company”), an emerging leader in DNA-based cancer diagnostics, announced today that it finalized and closed the purchase of the assets of Los Angeles-based Response Genetics, Inc. (“RGI”) on Friday, October 9, 2015.
Over ninety percent of the additional $10-$12 million in revenue that RGI will contribute to Cancer Genetics over the next year will be generated by business areas related to molecular profiling, therapeutic selection and patient monitoring in solid tumors, including lung, colorectal and skin cancers. The acquisition is also expected to add $4 million to CGI in future contract value from biopharma and clinical research clients. CGI will continue to expand the biopharma operations at RGI, which include strong historical relationships with major biopharma and pharmaceutical firms. Cancer Genetics will also continue to grow the clinical services that RGI’s Los Angeles-based laboratory provides to hundreds of medical care facilities and professionals across the country. To facilitate the transition and help develop future expansion plans, RGI’s Vice President of Operations, Alan Cheeks, will join the CGI management team and will be responsible for the day-to-day clinical and biopharma operations and delivery.
“The Response Genetics team is excited to become a part of the CGI family, to continue to expand our oncology-focused molecular diagnostic services and the delivery of information to improve patient insights and outcomes,” said Alan Cheeks, Vice President of Operations. “The combined company will provide global resources and expertise that uniquely positions CGI in the marketplace. As we move forward to develop a center of excellence in solid tumors on the West Coast, I’m certain we will see growth in our market share. CGI will benefit from increased demand and complexity in clinical trials and from our well positioned offering for the clinical oncology community.“
Additionally, CGI will continue working with the National Cancer Institute by providing the genomic testing for the multi-year Alchemist trials, which were awarded to Response Genetics in 2014. The trials involve genetic screening of tumor specimens removed during surgery for specific gene mutations and testing of post-operative treatment with drugs that target those mutations, but have only been approved by the FDA for use in advanced lung cancer. All screening, biomarker testing, and reporting will continue to be conducted at the Los Angeles-based lab, with substantial collaborations from other biotechology and pharmaceutical partners. Additional information on the Alchemist trials can be found at http://www.cancer.gov/newscenter/newsfromnci/2014/ALCHEMISTlaunchQandA.
CGI will also begin to immediately offer the FDA-cleared and Medicare reimbursed Tissue of Origin test. Developed initially by Pathwork Dx, the test has been at the genomic vanguard for diagnosing metastatic, poorly differentiated, and undifferentiated cancers. This proprietary, patented and FDA-cleared test will be offered to both biopharma and clinical customers, globally. CGI estimates that the clinical diagnostic market for this test is approximately $100 to $150 million annually in the United States given that there are over 31,000 new cases of cancer of unknown origin diagnosed in the U.S., according to the American Cancer Society. In alignment with CGI’s vision of providing greater access to clinically relevant and actionable genomic tools, CGI will also explore partnerships and distribution arrangements whereby the Tissue of Origin test can be readily offered by a network of partners and clinical partners, globally.
In addition to the integration of RGI facilities, a majority of the RGI staff, including a highly trained and nationally distributed sales force, will be brought into CGI’s existing structure. CGI will integrate over 20 of RGI’s clinically-focused sales professionals across the U.S., offering both a state-of-the-art molecular hematological portfolio along with a clinically actionable and validated portfolio of tests for solid tumors. The tests include a variety of methodologies–from IHC and FISH to gene-expression, microarrays as well as next-generation sequencing (NGS). The clinical operations will report to Mr. Alan Cheeks and Dr. Gary D. Zeger, the Medical Director of the Los Angeles facility. Mr. Cheeks will also be a part of the leadership team at CGI and will assume responsibility for helping to develop the center of excellence focused on solid tumor genomics and molecular profiling for clinical and biopharma customers.
“We look forward to a seamless integration of the Response Genetics team and facilities,” said Panna Sharma, President and CEO of Cancer Genetics. “Throughout the closing process, we’ve put a special focus on aligning our vision and operations to ensure that we will capture the synergies that exist between both companies. In addition to expanding our capabilities to include expertise in both solid and hematological cancers, we will also grow our national footprint significantly. Lastly, we will provide more actionable and relevant genetic information in formats that clinicians demand today. As a result of the integration, Response and CGI will offer the most complete bench to bedside oncology diagnostics in the marketplace with a unique portfolio of innovative clinical tests such as the Tissue of Origin test which will be a cornerstone of our suite of nine unique genomic tests and panels that are being offered today.”
As previously announced, the purchase price was approximately $14 million, which will include $7 million in cash and 788,584 shares of CGI common stock.
That is HUGE!!!! 0.10+ coming IMO!
in RGDXQ on the dip might do 0.10+!!
stop it..you and him are the same team LMAO
VTCQ +44% Great news out! next leg starting imo 0.02 coming shortly!
This stock is on the verge of break out! look at L2!!!
VTCQ UP 62% Major run commencing!
OK guys, looks like we are going to a new highs
VTCQ HUGE!! ASCM on the bid covering!!
VTCQ I am in! good news! this could do 0.02+
Great news out! what shorts are going to do now!
major squeeze! congrats to those held on the dip!
$VTCQ holy cow!!! this possibly could do 0.02 shortly!
VTCQ SHORT SQUEEZE HAS STARTED GUYS!
you see! 0.0084 now!
there isn't enough shares available at the ask!! short squeeze might happen here JMO!!
L2 getting really scary for shorts! 0.0079-0.0090-0.01 hard to cover fast!!
what are you talking about? 0.0079 getting hit 0.01+ coming
Shorts are starting to cover? 2 tic to 0.01!
mCig, Inc. Provides Corporate Update
Marketwire "Press Releases"
BEVERLY HILLS, CA -- (Marketwired) -- 11/05/15 -- mCig, Inc. (the "Company") (OTCQB: MCIG ), a leading distributor of innovative products, technologies, and services for the global medical and legal recreational cannabis industry, updates its shareholders on important progress made during the second quarter:
Operating Highlights for the Quarter Include:
Best Quarter in Company History. The company expects to report Revenue for the three months ended October 31, 2015 of approximately $850,000 .
The quarterly results highlight the successful business model undertaken by Management.
The company continues to improve expense management by taking a different approach to compensatory strategies. Management believes the current quarter can be the first in company history to register a net profit.
Creating diverse income streams through product-line launches that are developed, marketed, branded, and distributed by the company will be the primary focus moving forward.
Next week, the company will release its own CBD line of products together with VITACIG Inc. (OTC PINK: VTCQ).
This quarter MCIG will be launching a new online store that will contain a collection of the highest quality CBD tinctures/topicals/edibles/vapables on the market.
Another new project that will beta-test in the quarter will be www.mcigcannabox.com, which will be dedicated to providing innovative and holistic health products on a subscription basis.
"We're very pleased with the excellent progress the company achieved during the last quarter. For the coming quarter and beyond, we remain excited by the many initiatives we have in place for all our brands and projects," said Paul Rosenberg , President and Chief Executive Officer of MCIG .
About mCig, Inc.
Headquartered in Beverly Hills, CA , mCig, Inc. (OTCQB: MCIG ) is a leading provider of advanced technologies and solutions to the global cannabis industry. mCig manufactures and markets best-selling portable and home vaporizers, extraction related equipment, CBD Rich Hemp Oil-derived products, and related nutraceuticals based on natural compounds found in Cannabis and Hemp plants. The company owns the mCig and Vapolution brands, and has a 47% stake in VitaCig (VTCQ), makers of the VitaStik, a disposable vitamin vaporizer. The company believes that a well-regulated marijuana industry is emerging as more states follow the lead of Alaska , Colorado , Oregon , and Washington in legalizing marijuana. A similar trend is developing within the CBD and Hemp industries following overwhelming consumer demand.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
Contact: Paul Rosenberg CEO paul@mcig.org
Source: mCig, Inc.
Dip is over! done! ready for major bounce!
They all out on duty LOL
0.0092 X 0.0095 L2 setting up nicely for major bounce
Tomorrow green day here for sure!
stock was shorted heavenly! time for short squeeze!
Huge bid, time to go back up
I am in for a bounce play!
That's awesome!!! shorts hurry up and cover your A8$$ you are making those shorts nervous.
MAJOR BOUNCE COMING! Major shorts/news/8-k and NO HALT i am playing it fwiw
Consolidating here..watch a big & quick bounce
will bounce back fast again
HUGE BID!!
Next round to 0.02+ coming here IMO!
ASCM is on the bid coverrrrrring LOL
Break 0.02 is coming! shorts are getting nervous
HUGE SHORT SQUEEZE here! regardless of the $350 Million NEWS & FORM 8-K! I am playing the"bounce" fwiw
0.02 coming guys